Altimmune Inc ALT:NASDAQ

Last Price$9.48NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$9.45 (2)
Ask (Size)$9.58 (10)
Day Low / HighN/A - N/A
Volume836.7 K
 

View Biotechnology IndustryPeer Comparison as of 12/03/2021

 

Altimmune Inc ( NASDAQ )

Price: $9.48
Change: -0.64 (6.32%)
Volume: 836.7 K
4:00PM ET 12/03/2021
 
 

Information Services Group Inc ( NASDAQ )

Price: $7.90
Change: -0.20 (2.47%)
Volume: 244.5 K
4:00PM ET 12/03/2021
 
 

Comtex News Network Inc ( OTC )

Price: $20.02
Change: 0.00 (0.00%)
Volume: 1.00
9:30AM ET 9/22/2021
 
 

Emerald Holding Inc ( NYSE )

Price: $4.02
Change: -0.14 (3.37%)
Volume: 85.7 K
7:00PM ET 12/03/2021
 
 

Atomera Inc ( NASDAQ )

Price: $20.35
Change: -1.28 (5.92%)
Volume: 463.0 K
4:00PM ET 12/03/2021
 

Read more news Recent News

-- Earnings Flash (ALT) ALTIMMUNE Posts Q3 Revenue $0.2M, vs. Street Est of $0.071M
4:05PM ET 11/09/2021 MT Newswires

...

Altimmune Enrolls First Patient in Fatty Liver Disease Trial
8:30AM ET 10/04/2021 MT Newswires

Altimmune (ALT) said Monday it has enrolled the first patient in an early-stage trial of pemvidutide as a potential treatment for non-alcoholic fatty liver...

Sector Update: Health Care Stocks Decline Premarket Tuesday
9:13AM ET 9/28/2021 MT Newswires

Health care stocks were declining in Tuesday's premarket trading. The Health Care SPDR (XLV) was 0.63% lower and the iShares NASDAQ Biotechnology Index...

Sector Update: Health Care
8:55AM ET 9/28/2021 MT Newswires

Health care stocks were declining in Tuesday's premarket trading. The Health Care SPDR (XLV) was 0.7% lower and the iShares NASDAQ Biotechnology Index...

Company Profile

Business DescriptionAltimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on peptide-based therapeutics for obesity and liver diseases. The company is developing pemvidutide (ALT-801), a novel, GLP-1/glucagon dual agonist for the treatment of obesity and non-alcoholic steatohepatitis (NASH), and HepTcell(TM), an immunotherapeutic candidate for patients chronically infected with the hepatitis B virus (HBV). The company was founded in 1997 and is headquartered in Gaithersburg, MD. View company web site for more details
Address910 Clopper Road
Gaithersburg, Maryland 20878
Phone+1.240.654.1450
Number of Employees27
Recent SEC Filing12/01/20214
President, Chief Executive Officer & DirectorVipin K. Garg
Secretary, Chief Financial & Accounting OfficerWilliam M. Brown
Chief Scientific OfficerM. Scot Roberts
Chief Technology OfficerBertrand Georges

Company Highlights

Price Open$10.20
Previous Close$10.12
52 Week Range$8.10 - 24.61
Market Capitalization$376.7 M
Shares Outstanding39.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.91
Beta vs. S&P 500N/A
Revenue$10.3 M
Net Profit Margin-2,432.90%
Return on Equity-36.33%

Analyst Ratings as of 06/01/2021

Buy
7
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset